论文部分内容阅读
目的:研究妊娠期高血压疾病(HDCP)患者血浆中Chemerin的含量,以探讨其在HDCP发病机制中的作用,判断是否可作为HDCP一个新的预测标志物。方法:采用酶联免疫吸附法(ELISA)分别检测40例正常孕妇(对照组)和42例HDCP患者(试验组,其中轻度子痫前期17例、重度子痫11例、妊娠期高血压14例)中的血浆Chemerin水平,同时测定受试者的体质量指数(BMI)、血压,检测血糖、血脂、胰岛素等指标,比较两组的差异性。结果:妊娠期高血压疾病组(25.0±4.3)pg/ml血浆Chemerin含量明显高于对照组(9.5±3.2)pg/ml,差异有统计学意义(P<0.05),且重度子痫前期组(30.5±4.4)pg/ml明显高于轻度子痫前期(25.6±4.6)pg/ml和妊娠期高血压组(17.8±4.0)pg/ml(P<0.05);轻度子痫前期组高于妊娠期高血压组(P<0.05)。结论:在妊娠期高血压疾病组中Chemerin浓度是上升的,可作为识别可能有HDCP高危风险的孕妇的一个有价值的检测因子。
Objective: To study the content of Chemerin in the plasma of patients with hypertensive disorder of pregnancy (HDCP) to explore its role in the pathogenesis of HDCP and to determine whether it can be used as a new predictive marker of HDCP. Methods: Forty normal pregnant women (control group) and 42 HDCP patients (control group) were detected by enzyme linked immunosorbent assay (ELISA), including 17 cases of mild preeclampsia, 11 cases of severe eclampsia, 14 cases of gestational hypertension The plasma Chemerin levels were also measured. The body mass index (BMI), blood pressure, blood glucose, blood lipids, insulin and other indicators were also measured, and the differences between the two groups were compared. Results: The plasma levels of Chemerin in gestational hypertension group (25.0 ± 4.3) pg / ml were significantly higher than those in control group (9.5 ± 3.2) pg / ml, the difference was statistically significant (P <0.05), and severe preeclampsia (30.5 ± 4.4) pg / ml was significantly higher than that of mild preeclampsia (25.6 ± 4.6) pg / ml and gestational hypertension group (17.8 ± 4.0) pg / ml Higher than gestational hypertension group (P <0.05). Conclusions: Chemerin levels are elevated in gestational hypertension patients and may be a valuable test for identifying pregnant women at risk for HDCP.